Cancer-Cachexia-Induced Human Skeletal Muscle Myotube Degeneration Is Prevented via Cannabinoid Receptor 2 Agonism In...

Area of Science:

• Biomedical Sciences
• Cell Biology
• Pharmacology

Background:

• Cancer cachexia is a debilitating syndrome characterized by significant loss of skeletal muscle and fat mass, negatively impacting cancer patient outcomes.
• Currently, no approved therapies exist for cachexia, highlighting the urgent need for effective treatment strategies.

Purpose of the Study:

• To establish a reliable in vitro model of cancer-induced cachexia using mature human skeletal muscle myotubes.
• To utilize this model to evaluate the therapeutic potential of cannabinoid-related compounds in combating cachexia.

Main Methods:

• Mature human skeletal muscle myotubes were differentiated from primary myoblasts.
• Cancer cachexia models were established using conditioned media from human colon adenocarcinoma (SW480) and non-small-cell lung carcinoma (H1299) cell lines.
• Cannabinoid receptor expression (CB1R, CB2R) was confirmed, and the effects of various cannabinoid compounds (THC, JWH133, ART27.13) and receptor antagonists (AM630, Rimonabant) on myotube degeneration were assessed.

Main Results:

• Cancer cell conditioned media induced significant myotube degeneration, serving as a validated index of cachexia in the in vitro model.
• Tetrahydrocannabinol (THC), JWH133, and ART27.13 demonstrated protective effects against cancer cachexia-induced myotube degeneration.
• The protective effect of ART27.13 was abolished by the CB2 receptor antagonist AM630, but not by the CB1 receptor antagonist Rimonabant, indicating a CB2 receptor-mediated mechanism.

Conclusions:

• A robust and convenient in vitro model for studying cancer-induced human skeletal muscle cachexia has been successfully established.
• The cannabinoid compound ART27.13 shows significant therapeutic potential for preventing cancer cachexia.
• The protective effects of ART27.13 against cachexia are mediated through the CB2 receptor.